参考文献/References:
[1] 肖康,梁申芝,万光明,王莉.玻璃体内注射阿柏西普治疗顽固性糖尿病黄斑水肿的疗效[J].眼科新进展,2020,40(8):744-746.
XIAO K,LIANG S Z,WAN G M,WANG L.Efficiency of intravitreal aflibercept for the treatment of refractory diabetic macular edema[J].Rec Adv Ophthalmol,2020,40(8):744-746.
[2] SCHMIDT-ERFURTH U,GARCIA-ARUMI J,BANDELLO F,BERG K,CHAKRAVARTHY U,GERENDAS B S,et al.Guidelines for the Management of Diabetic Macular Edema by the European Society of Retina Specialists (EURETINA) [J].Ophthalmologica,2017,237(4):185-222.
[3] ELNAHRY A G,ELNAHRY G A.Optical coherence tomography angiography of macular perfusion changes after anti-VEGF therapy for diabetic macular edema:a systematic review [J].J Diabetes Res,2021,2021:6634637.
[4] URBANCIC M,KLOBUCAR P,ZUPAN M,URBANCIC K,LAVRIC A.Anti-VEGF treatment of diabetic macular edema:two-year visual outcomes in routine clinical practice[J].J Ophthalmol,2020,2020:6979758.
[5] WHITCUP S M,CIDLOWSKI J A,CSAKY K G,AMBATI J.Pharmacology of corticosteroids for diabetic macular edema [J].Invest Ophthalmol Vis Sci,2018,59(1):1-12.
[6] CHEUNG G C,YOON Y H,CHEN L J,CHEN S J,GEORGE T M,LAI T Y,et al.Diabetic macular oedema:evidence-based treatment recommendations for Asian countries [J].Clin Exp Ophthalmol,2018,46(1):75-86.
[7] CHHABLANI J,WONG K,TAN G S,SUDHALKAR A,LAUDE A,CHEUNG C M G,et al.Diabetic macular edema management in Asian population:expert panel consensus guidelines[J].Asia Pac J Ophthalmol (Phila),2020,9(5):426-434.
[8] 宋潇宇,朴天华.难治性糖尿病黄斑水肿治疗策略的研究进展[J].牡丹江医学院学报,2021,42(3):125-127,157.
SONG X Y,PU T H.Research progress of treatment strategies for refractory diabetic macular edema[J].J MuDanJiang Med Univ,2021,42(3):125-127,157.
[9] TING D S,CHEUNG G C,WONG T Y.Diabetic retinopathy:global prevalence,major risk factors,screening practices and public health challenges:a review [J].Clin Exp Ophthalmol,2016,44(4):260-277.
[10] URBANCIC M,GARDASEVIC TOPCIC I.Dexamethasone implant in the management of diabetic macular edema from clinician’s perspective [J].Clin Ophthalmol,2019,13:829-840.
[11] KODJIKIAN L,BELLOCQ D,BANDELLO F,LOEWENSTEIN A,CHAKRAVARTHY U,KOH A,et al.First-line treatment algorithm and guidelines in center-involving diabetic macular edema [J].Eur J Ophthalmol,2019,29(6):573-584.
[12] ROMERO-AROCA P,BAGET-BERNALDIZ M,PAREJA-RIOS A,LOPEZ-GALVEZ M,NAVARRO-GIL R,VERGES R.Diabetic macular edema pathophysiology:vasogenic versus inflammatory [J].J Diabetes Res,2016,2016:2156273.
[13] DARUICH A,MATET A,MOULIN A,KOWALCZUK L,NICOLAS M,SELLAM A,et al.Mechanisms of macular edema:beyond the surface [J].Prog Retin Eye Res,2018,63:20-68.
[14] BUX A V,FORTUNATO F,BARONE A,RUSSO V,DELLE NOCI N,IACULLI C.Early treatment with dexamethasone intravitreal implants in diabetic macular edema:naive versus refractory patients [J].Eur J Ophthalmol,2021,2021:11206721211024804.
[15] MEDINA-BAENA M,CEJUDO-CORBALAN O,GARCIA-PULIDO J I,HUERTOS-CARRILLO M J,GIRELA-LOPEZ E.Intravitreal dexamethasone implant in naive and previously treated patients with diabetic macular edema:a retrospective study [J].Int J Ophthalmol,2020,13(10):1597-1605.
[16] FURINO C,BOSCIA F,REIBALDI M,ALESSIO G.Intravitreal therapy for diabetic macular edema:an update [J].J Ophthalmol,2021,2021:6654168.
[17] MISHRA S K,SINHA S,CHAUHAN R,KUMAR A.Intravitreal dexamethasone implant versus intravitreal ranibizumab injection for treatment of non-proliferative diabetic macular edema:a prospective,randomized and blinded trial [J].Curr Drug Deliv,2020,[Online ahead of print].
[18] VUJOSEVIC S,SIMO R.Local and systemic inflammatory biomarkers of diabetic retinopathy:an integrative approach[J].Invest Ophthalmol Vis Sci,2017,58(6):BIO68-BIO75.
[19] TAKAYA K,SUZUKI Y,MIZUTANI H,SAKURABA T,NAKAZAWA M.Long-term results of vitrectomy for removal of submacular hard exudates in patients with diabetic maculopathy [J].Retina,2004,24(1):23-29.
[20] YU Q,WANG F,ZHOU L,YANG J,LIU K,XU X.Quantification of diabetic retinopathy lesions in DME patients with intravitreal conbercept treatment using deep learning[J].Ophthalmic Surg Lasers Imaging Retina,2020,51(2):95-100.
[21] YOON C K,SAGONG M,SHIN J P,LEE S J,LEE J E,LEE J E,et al.Title:efficacy of intravitreal dexamethasone implant on hard exudate in diabetic macular edema [J].BMC Ophthalmol,2021,21(1):41.
[22] BRESSLER S B,GLASSMAN A R,ALMUKHTAR T,BRESSLER N M,FERRIS F L,GOOGE J M Jr,et al.Five-year outcomes of ranibizumab with prompt or deferred laser versus laser or triamcinolone plus deferred ranibizumab for diabetic macular edema [J].Am J Ophthalmol,2016,164:57-68.
[23] LAUGESEN C S,OSTRI C,BRYNSKOV T,LUND-ANDERSEN H,LARSEN M,VORUM H,et al.Intravitreal ranibizumab for diabetic macular oedema in previously vitrectomized eyes [J].Acta Ophthalmol,2017,95(1):28-32.
[24] REZKALLAH A,MALCLES A,DOT C,VOIRIN N,AGARD E,VIE A L,et al.Evaluation of efficacy and safety of dexamethasone intravitreal implants of vitrectomized and nonvitrectomized eyes in a real-world study [J].J Ocul Pharmacol Ther,2018,34(8):596-602.
[25] SUDHALKAR A,KODJIKIAN L,CHHABLANI J,BHOJWANI D,VASAVADA A.Intraocular dexamethasone implant position in situ and ocular hypertension [J].Retina,2018,38(12):2343-2349.
[26] BILGIC A,SUDHALKAR A,KODJIKIAN L,VASAVADA V,VASAVADA S,BHOJWANI D,et al.Pro Re Nata Dexamethasone implant for treatment-Naive Phakic Eyes with diabetic macular edema:a prospective study[J].Ophthalmol Retina,2019,3(11):929-937.
[27] PACELLA F,PACELLA E,TROVATO BATTAGLIOLA E,MALVASI M,SCALINCI S Z,TURCHETTI P,et al.Efficacy and safety of intravitreal Fluocinolone Acetonide microimplant (ILUVIEN?) in patients with chronic diabetic macular edema:1 year follow-up [J].Eur J Ophthalmol,2021,2021:11206721211020203.
[28] MALCLES A,DOT C,VOIRIN N,VIE A L,AGARD E,BELLOCQ D,et al.Safety of intravitreal dexamethasone implant (OZURDEX):the SAFODEX study.Incidence and risk factors of ocular hypertension[J].Retina,2017,37(7):1352-1359.
[29] MACCUMBER M W.Intraocular pressure and anti-vascular endothelial growth factor injections [J].Ophthalmol Retina,2020,4(9):859-860.
[30] OZDEMIR O,ARMAN A,TAYMAN C.Intraocular pressure effect of anti-vascular endothelial growth factor injection for aggressive posterior retinopathy of prematurity [J].Graefes Arch Clin Exp Ophthalmol,2021,[Online ahead of print].
[31] BRESSLER S B,ALMUKHTAR T,BHORADE A,BRESSLER N M,GLASSMAN A R,HUANG S S,et al.Repeated intravitreous ranibizumab injections for diabetic macular edema and the risk of sustained elevation of intraocular pressure or the need for ocular hypotensive treatment [J].JAMA Ophthalmol,2015,133(5):589-597.
[32] 陈敏华,张小花,谢青,彭立.地塞米松玻璃体内植入剂对比雷珠单抗治疗糖尿病黄斑水肿的疗效及安全性的荟萃分析[J].临床与病理杂志,2021,41(3):615-622.
CHEN M H,ZHANG X H,XIE Q,PENG L.Efficacy and safety of intravitreal dexamethasone implant versus ranibizumab in diabetic macular edema:a Meta-analysis[J].J Clin Pathol Res,2021,41(3):615-622.
[33] AARONSON A,TAIPALE C,ACHIRON A,AALTONEN V,GRZYBOWSKI A,TUUMINEN R.Relationship between prolonged intraocular inflammation and macular edema after cataract surgery [J].Transl Vis Sci Technol,2021,10(7):15.
[34] ZIEMSSEN F,AGOSTINI H,Boyer R.Three-year,randomized,sham-controlled trial of dexamethasone intravitreal implant in patients with diabetic macular edema[J].Ophthalmology,2015,122(3):e20-21.
[35] KODJIKIAN L,BELLOCQ D,MATHIS T.Pharmacological management of diabetic macular edema in real-life observational studies[J].Biomed Res Int,2018,2018:8289253.
[36] FURINO C,BOSCIA F,NIRO A,D’ADDARIO M,GRASSI M O,SAGLIMBENE V,et al.Diabetic macular edema and cataract surgery:phacoemulsification combined with dexamethasone intravitreal implant compared with standard phacoemulsification [J].Retina,2021,41(5):1102-1109.
[37] FALLICO M,AVITABILE T,CASTELLINO N,LONGO A,RUSSO A,BONFIGLIO V,et al.Intravitreal dexamethasone implant one month before versus concomitant with cataract surgery in patients with diabetic macular oedema:the dexcat study [J].Acta Ophthalmol,2021,99(1):e74-e80.